These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 25105431)

  • 1. [The glutamate hypothesis of schizophrenia].
    Hasan A; Malchow B; Falkai P; Schmitt A
    Fortschr Neurol Psychiatr; 2014 Aug; 82(8):447-56. PubMed ID: 25105431
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Glutamate and schizophrenia: phencyclidine, N-methyl-D-aspartate receptors, and dopamine-glutamate interactions.
    Javitt DC
    Int Rev Neurobiol; 2007; 78():69-108. PubMed ID: 17349858
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Glutamatergic mechanisms in schizophrenia.
    Tsai G; Coyle JT
    Annu Rev Pharmacol Toxicol; 2002; 42():165-79. PubMed ID: 11807169
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The glutamate hypothesis: a pathogenic pathway from which pharmacological interventions have emerged.
    Veerman SR; Schulte PF; de Haan L
    Pharmacopsychiatry; 2014 Jul; 47(4-5):121-30. PubMed ID: 25002292
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Significance of dysfunctional glutamatergic transmission for the development of psychotic symptoms.
    Pietraszek M
    Pol J Pharmacol; 2003; 55(2):133-54. PubMed ID: 12926541
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Activation of glutamate neurotransmission in the prefrontal cortex sustains the motoric and dopaminergic effects of phencyclidine.
    Takahata R; Moghaddam B
    Neuropsychopharmacology; 2003 Jun; 28(6):1117-24. PubMed ID: 12700703
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Hypoglutamatergic hypothesis of schizophrenia: evidence from genetic studies].
    Itokawa M; Yoshikawa T
    Seishin Shinkeigaku Zasshi; 2003; 105(11):1349-62. PubMed ID: 14758783
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mechanism of action of antipsychotic drugs: from dopamine D(2) receptor antagonism to glutamate NMDA facilitation.
    Laruelle M; Frankle WG; Narendran R; Kegeles LS; Abi-Dargham A
    Clin Ther; 2005; 27 Suppl A():S16-24. PubMed ID: 16198197
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Glutamatergic neurotransmission modulation and the mechanisms of antipsychotic atypicality.
    Heresco-Levy U
    Prog Neuropsychopharmacol Biol Psychiatry; 2003 Oct; 27(7):1113-23. PubMed ID: 14642971
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Glycine therapy of schizophrenia; its rationale and a review of clinical trials].
    Semba J
    Nihon Shinkei Seishin Yakurigaku Zasshi; 1998 Jun; 18(3):71-80. PubMed ID: 9800198
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Glutamate in schizophrenia: clinical and research implications.
    Goff DC; Wine L
    Schizophr Res; 1997 Oct; 27(2-3):157-68. PubMed ID: 9416645
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The neuropsychopharmacology of phencyclidine: from NMDA receptor hypofunction to the dopamine hypothesis of schizophrenia.
    Jentsch JD; Roth RH
    Neuropsychopharmacology; 1999 Mar; 20(3):201-25. PubMed ID: 10063482
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Glutamate hypothesis of schizophrenia and targets for new antipsychotic drugs].
    Hashimoto K; Iyo M
    Nihon Shinkei Seishin Yakurigaku Zasshi; 2002 Feb; 22(1):3-13. PubMed ID: 11917507
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Glutamatergic hypothesis of schizophrenia: psychoses induced by phencyclidine and cortical-subcortical imbalance].
    Krebs MO
    Encephale; 1995; 21(5):581-8. PubMed ID: 8529568
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Glutaminergic hypothesis of schizophrenia: clinical research studies with ketamine].
    Mechri A; Saoud M; Khiari G; d'Amato T; Dalery J; Gaha L
    Encephale; 2001; 27(1):53-9. PubMed ID: 11294039
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Role of central glutamatergic neurotransmission in the pathogenesis of psychiatric and behavioral disorders.
    Wang SJ; Yang TT
    Drug News Perspect; 2005 Nov; 18(9):561-6. PubMed ID: 16421629
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Role of excitatory amino acids in neuropathology].
    Wikinski SI; Acosta GB
    Medicina (B Aires); 1995; 55(4):355-65. PubMed ID: 8728878
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The role of glutamate on the action of antidepressants.
    Hashimoto K
    Prog Neuropsychopharmacol Biol Psychiatry; 2011 Aug; 35(7):1558-68. PubMed ID: 20600468
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Glutamatergic aspects of schizophrenia.
    Tamminga C
    Br J Psychiatry Suppl; 1999; (37):12-5. PubMed ID: 10211134
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Animal model of schizophrenia: dysfunction of NMDA receptor-signaling in mice following withdrawal from repeated administration of phencyclidine.
    Nabeshima T; Mouri A; Murai R; Noda Y
    Ann N Y Acad Sci; 2006 Nov; 1086():160-8. PubMed ID: 17185514
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.